KRAS and colorectal carcinoma: CRC is characterized by the hyperactivation of oncogenes (KRAS, BRAF, and PIK3CA) and the loss of tumor suppressor genes (TP53 and PTEN), along with irregularities in multiple signaling pathways [25].